盐酸环喷托酯滴眼液与阿托品眼膏在儿童验光中的比较

目的：探讨应用1%盐酸环喷托酯滴眼液对3~12岁视力低下儿童进行散瞳验光的可行性。方法对80例（160眼）视力低下儿童先后用1%盐酸环喷托酯滴眼液与1%阿托品眼膏进行散瞳验光,将两种散瞳剂的验光结果进行对比。按屈光状态分为远视组、近视组和散光组;其中散光值是将柱镜独立分出统计。结果散光组两种散瞳剂的验光结果间差异无统计学意义,远视组、近视组的两种验光结果间有显著性差异并存在相关性。结论1%盐酸环喷托酯滴眼液仍无法替代1%阿托品成为儿童常规散瞳验光用药。但对于单纯的散光的儿童,可用1%盐酸环喷托酯滴眼液替代1%阿托品眼膏进行散瞳验光。     

国产盐酸环喷托酯滴眼液和托吡胺对眼睫状肌麻痹效果的比较研究

目的:观察国产盐酸环喷托酯滴眼液对人眼睫状肌麻痹和瞳孔散大的效果。方法:入选者48例左右眼随机分入试验组和对照组,分别滴用10g/L盐酸环喷托酯滴眼液和托吡卡胺滴眼液,每次1滴,隔5min再滴1次。于给药前1/6,给药后1/3,3/4,5/4,24,48h检查瞳孔直径和残余调节量。结果:国产盐酸环喷托酯的散瞳效应较托吡卡胺弱(P<0.01),但持续时间较长(P<0.01);盐酸环喷托酯的麻痹睫状肌效应较托吡卡胺强(P<0.01),持续时间也较长(P<0.01)。结论:盐酸环喷托酯滴眼液是一种安全有效的睫状肌麻痹剂,其麻痹睫状肌的效果优于托吡卡胺。     

盐酸环喷托酯对儿童睫状肌麻痹效果的观察

目的:探讨盐酸环喷托酯滴眼液对屈光不正儿童验光睫状肌麻痹的效果。方法:对6～12岁屈光不正儿童60例120眼随机分为3组,分别用盐酸环喷托酯滴眼液、复方托吡卡胺滴眼液及阿托品眼膏滴眼。在用药前及用药后不同时间点对3组患者分别在电脑验光仪上进行客观验光并测量瞳孔直径,在综合验光仪上进行主观验光并用移近法测量调节力和剩余调节力。结果:盐酸环喷托酯滴眼液最大睫状肌麻痹时间是60min,在最大睫状肌麻痹状态下盐酸环喷托酯组剩余调节力较复方托吡卡胺组小(P<0.05),与阿托品组相近(P>0.05)。结论:用盐酸环喷托酯代替阿托品对6～12岁屈光不正非斜视儿童进行散瞳验光是可行的。     

盐酸环喷托酯滴眼液和复方托品卡胺睫状肌麻痹效果比较

目的:了解盐酸环喷托酯滴眼液和复方托品卡胺滴眼液在散瞳验光中麻痹睫状肌的临床效果,客观地对其评价以指导临床工作。 方法:随机抽取2010-12/2011-03期间的60例120眼屈光不正（近视和远视各占50%）患者,年龄12～40岁,利用国产复方托品卡胺滴眼液滴眼散瞳先后对其进行散瞳4次, 45min以后,对其进行检影验光,并利用综合验光仪测定其残余调节量,第2d用盐酸环喷托酯眼液进行复验。 结果:远视组盐酸环喷托酯滴眼液和复方托品卡胺两者验光结果差异较大（P＜0.01）;近视组两者验光差异较小（P＜0.05）,但是仍然具有统计学差异。 结论:临床上对于屈光不正患者的屈光检查,复方托品卡胺滴眼液是一种有效的睫状肌麻痹剂,但因注意到其麻痹睫状肌及放松调节的有限性,特别在远视患者应灵活结合其他放松调节如盐酸环喷托酯眼液的方法获取最终的配镜处方。     

盐酸环喷托酯滴眼液在儿童屈光状态检查中的应用

目的：探讨10 g/L盐酸环喷托酯滴眼液在小儿屈光状态检查中的应用。比较其与阿托品在散瞳验光中麻痹睫状肌的效果,用以指导临床工作。
　　方法：采用自身配对设计方法,对年龄3~12岁118例236眼(其中近视40例80眼,远视78例156眼,合并有散光73例146眼)先采用10 g/L盐酸环喷托酯滴眼液滴眼3次散瞳(每次间隔5min),末次点眼1h后进行检影验光。间隔3d后重新点10g/L阿托品眼膏1wk(每晚1次)重新进行散瞳检影验光。按屈光度分成近视组、远视组、散光组,其中散光度数是将柱镜度数独立分离出来统计。将两种散瞳药的验光结果进行比较。
　　结果：近视组使用两种方法散瞳验光后屈光度值分别为-2.25±1.31D,-2.23±1.32D,差异无统计学意义( P=0.109);远视组应用两种药物散瞳验光后屈光度分别为3.76±2.4D,4.39±2.6D,差异有统计学意义(P=0.000);散光组应用两种药物散瞳验光后屈光度值分别为1.35±1.19D,1.38±2.00D,差异无统计学意义(P=0.374)。
　　结论：盐酸环喷托酯滴眼液可用于临床上3~12岁近视、散光儿童的散瞳验光。但在远视儿童初次就诊仍需点阿托品眼膏散瞳验光。     

盐酸环喷托酯滴眼液在儿童远视验光中的应用

目的：比较盐酸环喷托酯滴眼液和阿托品眼用凝胶在12岁以下远视儿童散瞳检影验光结果,以评估盐酸环喷托酯滴眼液在远视验光中的临床使用价值。

方法：年龄2～12岁的远视儿童51例102眼,先用10g/L盐酸环喷托酯滴眼液连续点眼5次后验光,间隔1d后,再用10g/L硫酸阿托品眼用凝胶连续点眼3d后进行散瞳检影验光。分析比较两种睫状肌麻痹剂在不同屈光组的验光结果及全身不良反应。

结果：轻度远视31眼两种验光结果无统计学差异(P>0.05),中度远视组39眼两种验光结果无统计学差异(P>0.05),高度远视组32眼两种验光结果无统计学差异(P>0.05)。10g/L盐酸环喷托酯滴眼液的全身不良反应发生率为2%,10g/L阿托品眼用凝胶全身不良反应发生率为8%。

结论：盐酸环喷托酯滴眼液是一种起效快、作用强、持续时间短的安全有效的新型睫状肌麻痹剂,临床上可广泛应用。     

盐酸环喷托酯和阿托品对远视儿童睫状肌麻痹效果的比较

目的:比较盐酸环喷托酯与阿托品对远视儿童睫状肌麻痹效果,以评估盐酸环喷托酯的临床使用价值。方法:对96例192眼远视儿童进行观察,先用盐酸环喷托酯滴眼液,后用阿托品眼膏,分析比较两种药物睫状肌麻痹后的验光结果和观察药物的不良反应。结果:两组睫状肌麻痹后的验光结果差异无显著性(P>0.05)。盐酸环喷托酯组未见明显药物不良反应,低于阿托品组(12.5%)。结论:盐酸环喷托酯是一种强效、快速且安全的睫状肌麻痹剂,值得临床推广应用,尤其适合远视儿童的睫状肌麻痹验光检查。     

盐酸环喷托酯滴眼液在近视儿童散瞳验光中的应用

目的分析1%盐酸环喷托酯滴眼液（赛飞杰）对3-12岁近视儿童散瞳验光的结果,探讨其在3-12岁近视儿童散瞳验光中应用的可行性。方法对58例（116只眼）年龄3-12岁近视儿童患者,分别用1%盐酸环喷托酯滴眼液和1%阿托品眼膏散瞳验光,比较两种方法的验光结果。结果 1%盐酸环喷托酯滴眼液与1%阿托品眼膏散瞳后球镜值和柱镜值差异无显著性,P0.05。球镜值在116只眼中,结果相同或相差≤0.50D者114只眼,相差≥0.75D者2只眼,球镜值符合率为98.28%。柱镜值在68只眼中,结果相同或相差≤0.25D者67只眼,相差≥0.75D者1只眼,符合率为98.53%。各年龄组球镜值和柱镜值符合率均在95%以上,差异无统计学意义,P0.05。结论 1%盐酸环喷托酯滴眼液是一种安全有效的睫状肌麻痹剂,可用于3-12岁近视儿童散瞳验光。     

远视儿童应用1％环喷托酯睫状肌麻痹验光的研究

目的 探讨远视儿童应用1％环喷托酯滴眼液以及联合应用表面麻醉药丙美卡因滴眼液的远视屈光度的峰值时间,并比较应用1％环喷托酯与1％阿托品睫状肌麻痹验光的屈光度值的差异.方法 采用简单随机化分组方法将71例(141只眼)远视儿童[年龄(7.9±2.1)岁]分为A组(Pro +Cyc组)和B组(NS+ Cyc组).两组均于1...     

盐酸环喷托酯、复方托吡卡胺与阿托品对儿童睫状肌麻痹效果的比较

目的：探讨盐酸环喷托酯、复方托吡卡胺与阿托品对不同年龄、屈光状态及调节性内斜视儿童的睫 状肌麻痹效果。方法：前瞻性临床研究。对2018年9月至2019年9月在武汉大学人民医院眼科就诊 的3～12岁屈光不正儿童283例（566眼）行睫状肌麻痹验光。所有患儿均先使用1%阿托品眼用凝胶 点眼后电脑验光,并随机分为A组和B组。2组均按年龄分为3～<6岁组和6～<12岁组,3～<6岁组 和6～<12岁组再分为无内斜近视组、无内斜远视组和伴内斜视组3个亚组。5周后,瞳孔大小及对光 反射恢复正常,A组使用1%盐酸环喷托酯滴眼液点眼后电脑验光,B组使用0.5%复方托吡卡胺滴眼 液点眼后电脑验光。采用Wilcoxon符号秩和检验对1%阿托品睫状肌麻痹前后电脑验光等效球镜度 （SE）差值、不同药物睫状肌麻痹后电脑验光差值进行统计分析。结果：1%阿托品散瞳后SE较散瞳 前偏正,SE差值为1.75（1.00～2.75）D,差异有统计学意义（Z=-20.62,P<0.001）。差异在3～<6岁 儿童、无内斜远视儿童及伴内斜视儿童中更明显（P<0.001）。A组使用1%阿托品散瞳后SE较使用 1%盐酸环喷托酯后偏正,SE差值为0.25（0.13～0.50）D（Z=-11.49,P<0.001）。3～<6岁组使用1% 阿托品后和使用1%盐酸环喷托酯后的SE差值在无内斜近视组、无内斜远视组和伴内斜视组分别为 0.25（0.25～0.25）D、0.38（0.25～0.50）D、0.50（0.38～0.75）D（Z=-3.34、-7.36、-4.95,均 P<0.001）。6～<12岁组的SE差值在3组为0（0～0.12）D、0.25（0.12～0.25）D、0.44（0.28～0.69）D （Z=-0.83,P=0.405;Z=-5.30,P<0.001;Z=-3.53,P<0.001）。B组使用1%阿托品散瞳后SE较使用0.5% 复方托吡卡胺后偏正,SE差值为0.25（0.13～0.50）D（Z=-15.46,P<0.001）。3～<6岁组使用1%阿 托品后和使用0.5%复方托吡卡胺后的SE差值在无内斜近视组、无内斜远视组和伴内斜视组分别为 0.25（0.19～0.25）D、0.38（0.25～0.75）D、0.69（0.30～1.03）D（Z=-3.15,P=0.002,Z=-9.89, P<0.001,Z=-4.79,P<0.001）。6～<12岁组的SE差值在3组分别为0（0～0.12）D、0.32（0.13～0.38）D、 0.50（0.41～0.50）D（Z=-1.37,P=0.171;Z=-7.15,P<0.001;Z=-4.37,P<0.001）。结论：1%盐酸环 喷托酯滴眼液或0.5%复方托吡卡胺滴眼液点眼后散瞳验光SE与1%阿托品眼用凝胶点眼后散瞳验光 的SE在6～<12岁无内斜视的近视儿童中相近,在3～<6岁和6～<12岁远视及伴内斜视儿童中存在 差异。     

不同年龄及不同进展程度的近视患者3种验光方法的选择时机

目的　探讨不同进展程度及不同年龄的近视患者选择小瞳验光、复方托吡卡胺散瞳后验光及阿托品散瞳后验光的时机。方法　将年龄7～18岁的304例近视患者按复诊的戴镜视力或初诊的裸眼视力分为3组:0.1～0.3组、0.4～0.6组、0.7～0.9组。所有患者根据不同年龄段（7～9岁、10～12岁、13～15岁、16～18岁）分别进行小瞳验光、复方托吡卡胺散瞳后验光及阿托品散瞳后验光,记录各组患者屈光度。结果　视力下降至0.1～0.3时,不同年龄段患者三种验光方式所得屈光度比较,差异无统计学意义（P>0.05）。结果显示各年龄段近视患者采用小瞳验光、复方托吡卡胺散瞳后验光、阿托品散瞳后验光的屈光度变化不明显。视力下降至0.4～0.6时,7～12岁近视患者复方托吡卡胺散瞳后验光、阿托品散瞳后验光都比小瞳验光所得屈光度低,而阿托品散瞳后验光所得屈光度降低更显著;13～18岁近视患者复方托吡卡胺散瞳后验光、阿托品散瞳后验光所得屈光度均低于小瞳验光所得屈光度,但其降低的差异随着年龄增长更加不明显。视力下降至0.7～0.9时,各年龄段近视患者小瞳验光、复方托吡卡胺散瞳后验光、阿托品散瞳后验光所得屈光度差异均有统计学意义（均为P＜0.05）。各年龄段近视患者小瞳验光、复方托吡卡胺散瞳后验光、阿托品散瞳后验光所得屈光度之间两两比较,差异均有统计学意义 （均为P＜0.05）。结果显示与小瞳验光所得结果相比,复方托吡卡胺散瞳后验光和阿托品散瞳后验光所得屈光度均降低,而阿托品散瞳后验光结果降低更显著。结论　视力下降至0.1～0.3的不同年龄患者可采用小瞳验光。视力下降至0.4～0.6的12岁以上近视患者可采用复方托吡卡胺散瞳后验光。视力下降至0.4～0.6的12岁以下近视患者和视力下降至0.7～0.9的各年龄段患者均需采用阿托品散瞳后验光。     

Comparison of Cyclopentolate,Compound Tropicamide and Atropine on Cycloplegiain Children

Objective: To investigate and compare the cycloplegic effect of cyclopentolate, compound topicamide and atropine in children with different ages, refractive status and accommodative esotropia. Methods: This prospective clinical study had been conducted at Renmin Hospital of Wuhan University between September 2018 and September 2019 in 283 children (566 eyes) of 3-12 years old with refractive error. All the children were given 1% atropine to obtain the refractive diopter, and they were randomly divided into group A and group B. The two group are divided into 3-<6 years old group and 6-<12 years old group according to age. The 3-<6 years old group and the 6-<12 years old group are divided into three subgroups: The myopia group without esotropia, the hyperopia group without esotropia and the esotropia group. After 5 weeks, pupil size and light reflex back to normal. Group A received 1% cyclopentolate hydrochloride eye drops for computer optometry, and group B received 0.5% compound tropicamide eye drops for computer optometry. The Wilcoxon signed rank sum test was used to statistically analyze the difference of spherical equivalent of computer optometry before and after 1% atropine, and the difference of computer optometry after different cycloplegia. Results: The SE after 1% atropine was greater than before 1% atropine, the difference of SE was 1.75(1.00-2.75)D, and the difference was statistically significant (Z=-20.62, P<0.001). The difference was more obvious children with aged 3 to 6, children with hyperopia and children with esotropia (P<0.001). In group A, the SE after using 1% atropine was greater than that after using 1% cyclopentolate, and the difference of SE was 0.25(0.13-0.50)D (Z=-11.49, P<0.001). The difference of SE in 3-<6 years old group after using 1% atropine and 1% cyclopentolate in the myopia group without esotropia, hyperopia group without esotropia and esotropia group were 0.25(0.25-0.25)D, 0.38(0.25-0.50)D, 0.50(0.38-0.75)D (Z=-3.34, -7.36, -4.95, all P<0.001). The difference of SE of that 3 subgroups in the 6-<12 years group were 0(0-0.12)D, 0.25(0.12-0.25)D, 0.44(0.28-0.69)D (Z=-0.83, P=0.405; Z=-5.30, P<0.001; Z=-3.53, P<0.001). In group B, the SE after using 1% atropine was greater than that after using 0.5% compound tropicamide, and the difference of SE was 0.25(0.13-0.50)D (Z=-15.46, P<0.001). The difference of SE in 3-<6 years old group after using 1% atropine and 0.5% compound tropicamide in the myopia group without esotropia, hyperopia group without esotropia and esotropia group were 0.25(0.19- 0.25)D, 0.38(0.25-0.75)D, 0.69(0.30-1.03)D (Z=-3.15, P=0.002; Z=-9.89, P<0.001; Z=-4.79, P<0.001). The difference of SE of that 3 subgroups in the 6-<12 years group were 0(0-0.12)D, 0.32(0.13-0.38)D, 0.50(0.41-0.50)D (Z=-1.37, P=0.171; Z=-7.15, P<0.001; Z=-4.37, P<0.001). Conclusions: The spherical equivalent of mydriasis refraction with 1% cyclopentolate eye drops or 0.5% compound tropicamide eye drops is similar to that with 1% atropine in myopic children aged 6 to 12 years without esotropia, and it is different from that with 1% atropine in 3-<6 years old children and children with hyperopia and esotropia at 6-<12 years old.     

青少年近视综合验光与散瞳验光屈光度分析

目的:探讨初诊12～16岁青少年近视在应用综合验光仪验光与美多丽散瞳后验光,其结果的比较及临床意义。方法:在我院2009-01/09患者中随机抽取100例200眼初诊患者,年龄12～16(平均14.5)岁,其中男80眼,女120眼。近视在0.50～4.50DS,散光在0.50～2.00DC,对其进行基础检查,排除眼病。将综合验光仪验光得出的结果和美多丽P散瞳后插片验光得出的结果进行比较。结果:综合验光仪验光者屈光度的均值为-1.68±0.80D,美多丽P散瞳后插片验光者屈光度的均值为-1.54±0.80D,综合验光仪验光得出的结果比美多丽P散瞳后插片验光得出的结果高,差异有显著意义(P<0.05)。结论:对于初诊的12～16岁青少年近视患者,临床中还要广泛地应用美多丽P散瞳验光,比小瞳下综合验光仪验光结果更加可靠。     

白内障患者超声乳化术中瞳孔直径变化的临床分析

目的:研究白内障患者超声乳化术中瞳孔直径的变化,了解其对白内障超声乳化术影响。方法:区组设计,前瞻性研究。选取60例60眼白内障手术患者,根据年龄分为两组,年轻组(A组)20例2 0眼和老年组(B组)4 0例4 0眼。术前均采用复方托吡卡胺滴眼液充分散瞳,术中计算机软件处理图像,并且根据角膜的放大比例测量以下手术时相的瞳孔直径:作角膜隧道切口前(t1)、注入黏弹剂后(t2)、人工晶状体植入前(t3)、手术结束即刻(t4)。采用SPSS 18.0统计软件分析数据。结果:患者t1~t4的瞳孔直径测量值依次为:A组8.36±0.65,8.97±0.50,8.67±0.63,8.72±0.96mm;B组7.73±0.58,8.23±0.59,7.89±0.16,7.70±0.63mm。两组间总体的比较:在手术的不同时相,瞳孔直径测量值存在组间差别(F=26.696,P<0.05);两组中,在不同时间点的比较:t1~t4时相的瞳孔直径,A组均大于B组,差异有统计学意义(P<0.05)。各组患者的瞳孔直径测量值在手术的不同时相有变化的趋势(F=23.423,P<0.05),且两组变化趋势比较无显著性差异(F=2.617,P>0.05);同一组中,不同时间点的比较:各组内t2时相的瞳孔直径测量值均大于t1时相测量值,差异有统计学意义(P<0.05);各组内术中t2~t4时相瞳孔直径测量值两两比较,A组差异均无统计学意义(P>0.05),B组t3和t4时相瞳孔直径减小,差异均有统计学意义(P<0.05)。结论:复方托吡卡胺滴眼液术前散瞳下,年轻白内障患者和老年白内障患者均可达到手术所需散瞳效果,老年白内障患者超声乳化术中瞳孔稳定性低于年轻白内障患者。     

青少年屈光不正患者扩瞳后验光结果与配镜处方的比较分析

目的：比较青少年屈光不正患者扩瞳后电脑验光、扩瞳后试镜与配镜处方的差异,探讨青少年屈光不正验光配镜的重点和注意事项。

方法：选取334例青少年屈光不正患者(包括212例近视和122例远视),进行扩瞳后电脑验光并试镜,恢复自然瞳孔后再试镜确定配镜处方。回顾性分析扩瞳后电脑验光、扩瞳后试镜和配镜处方之间的差异。

结果：扩瞳后电脑验光和扩瞳后试镜之间,总体数据中球镜和轴向的差异具有统计学意义(P<0.05),近视组中球镜、柱镜和轴向的差异均具有统计学意义(P<0.05),远视组中轴向的差异具有统计学意义(P<0.05)。总体数据和远视组中,扩瞳后电脑验光、扩瞳后试镜与配镜处方的球镜和轴向的差异有统计学意义(P<0.05)。远视组中扩瞳后电脑验光和扩瞳后试镜的球镜均大于配镜处方,且扩瞳后试镜与配镜处方柱镜的差异也有统计学意义(P<0.05)。近视组中扩瞳后电脑验光与配镜处方的球镜、柱镜和轴向的差异均有统计学意义(P<0.05),扩瞳后试镜与配镜处方的柱镜和轴向的差异均有统计学意义(P<0.05)。Bland-Altman分析提示,无论屈光性质,扩瞳后电脑验光和扩瞳后试镜的球镜、柱镜存在较好一致性,二者之间的差异在临床上可以接受,而轴向的一致性则较差。Bland-Altman分析提示,总体数据和远视组中,扩瞳后电脑验光、扩瞳后试镜分别与配镜处方的球镜和轴向的一致性较差,柱镜则存在较好一致性。近视组中扩瞳后电脑验光、扩瞳后试镜分别与配镜处方的球镜、柱镜具有较好的一致性,轴向的一致性则较差。

结论：扩瞳后电脑验光、扩瞳后试镜结果均不能作为配镜处方。扩瞳后电脑验光与扩瞳后试镜之间的差异有统计学意义,二者的球镜、柱镜存在较好的临床一致性。扩瞳后电脑验光和扩瞳后试镜的轴向不具有一致性,二者与配镜处方的一致性也较差。所以复光试镜时要加强对轴向的反复验证。     

环喷托酯单独用药和环喷托酯-复方托吡卡胺联合用药的睫状肌麻痹效果比较

目的：比较6～12岁儿童单独使用1%环喷托酯和1%环喷托酯-复方托吡卡胺联合用药的睫状肌麻痹 效果。方法：前瞻性随机对照研究。2018年7─9月在北京市海淀区妇幼保健院进行睫状肌麻痹验光 的6～12岁屈光不正儿童98例（98眼）,根据随机数字表法随机分为单独用药组和联合用药组。单独 用药组给予1%环喷托酯点眼3次;联合用药组给予1%环喷托酯点眼3次和复方托吡卡胺点眼2次。 分别于点眼前,第1次点眼后30、45、75 min测量等效球镜度（SE）和瞳孔直径。使用独立样本t检验 比较2组基线数据。采用重复测量资料的方差分析对不同给药方法在不同时间SE和瞳孔直径的影响 进行分析。使用Pearson相关性分析睫状肌麻痹程度与瞳孔散大程度之间的关系。结果：2组SE值均 在点眼后30 min内向正值方向发展,45 min达到最佳效果,45～75 min基本保持平稳,不同时间点睫 状肌麻痹作用差异有统计学意义（F=57.06,P<0.001）。不同给药方式对睫状肌麻痹效果影响差异无 统计学意义。随时间延长,不同给药方式睫状肌麻痹效果差异无统计学意义。点眼后2组瞳孔直径 均随时间延长而增大,时间因素引起瞳孔直径变化差异有统计学意义（F=502.87,P<0.001）。联合用 药组瞳孔直径大于单独用药组（F=30.63,P<0.001）,随时间延长,联合用药组瞳孔直径均大于单独 用药组,差异有统计学意义（F=13.53,P<0.001）。2组点眼后75 min SE改变值与瞳孔直径增加值之 间均无相关性。结论：在我国6～12岁儿童中,1%环喷托酯-复方托吡卡胺联合用药在睫状肌麻痹效 果、起效时间以及持续时间方面均未优于1%环喷托酯单独用药,而联合用药后瞳孔散大的不良反 应明显大于单独用药。     

Comparative Study on Cycloplegia with Cyclopentolate Alone and Cyclopentolate Combined with a Tropicamide Compound

Objective: To study cycloplegia using 1% cyclopentolate alone and 1% cyclopentolate combined with a tropicamide compound in children aged 6-12 years. Methods: In this prospective randomized controlled study, 98 children aged 6-12 years with ametropia were randomly divided into two groups: One group was given 1% cyclopentolate 3 times, the other group was given 1% cyclopentolate 3 times and a tropicamide compound 2 times. The spherical equivalent and pupil diameter were measured before and 30 min, 45 min and 75 min after the first eyedrop. The baseline data of the 2 groups were compared by an independent-samples t test. ANOVA of repeated measures was used to analyze the influence of the different methods on thesphericity equivalent (SE) and pupil diameter at different times. The correlation between the degree of cycloplegia and mydriasis was analyzed by Pearson correlation analysis. Results: The negative sphericity of the two groups decreased rapidly within 30 minutes after the first drop, the best effect was achieved in 45 minutes, and remained stable from 45 minutes to 75 minutes. The cycloplegia between different time points were statistically different (F=57.06, P<0.001) but there was no significant difference between the 2 methods. As time progressed, the difference in cycloplegia between the 2 methods was not significant. The pupil diameter of the 2 groups increased with the progression of time and was statistically significant (F=502.87, P<0.001). The pupil diameter of the group with the compound was larger than that of the single group (F=30.63, P<0.001), and as time progressed, the difference was also statistically significant (F=13.53, P<0.001). There was no correlation between the decrease in the negative SE and the increase in pupil diameter in the 2 groups. Conclusions: In children aged 6-12 years, the cycloplegia effect, onset time and duration of 1% cyclopentolate combined with a tropicamide compound are not better than that of 1% cyclopentolate alone, but mydriasis with the compound is significantly greater than 1% cyclopentolate alone.     

Comparison of effects of mydriatic drops (1% cyclopentolate and 0.5% tropicamide) on anterior segment parameters

Purpose:The purpose of this study is to investigate and compare the effects of cyclopentolate and tropicamide drops on anterior segment parameters in healthy individuals.Methods:Two hundred and fifty-eight eyes of 129 healthy volunteers were included in this randomized clinical study. Cyclopentolate 1% drop was applied to 75 (58%) participants (group 1) and tropicamide 0.5% drop was applied to 54 (42%) participants (group 2). Flat keratometry (K1), steep keratometry (K2), axial length (AL), central corneal thickness (CCT), anterior chamber depth (ACD), white-to-white (WTW) distance, pupil diameter, total pupil offset and intraocular lens (IOL) power were measured before and after drops, using Lenstar 900 optical biometry.Results:The increase in CCT, ACD, pupil diameter, and pupil offset was significant in group 1 after the drop (P < 0.05), while the increase in ACD, pupil diameter, and pupil offset was significant in group 2 (P < 0.05). When the two groups were compared, there was no significant difference in K1, K2, CCT, ACD, WTW, pupil diameter, pupil offset, and IOL power (using Sanders–Retzlaff–Kraff T formula) changes after drops (P > 0.05), whereas the change in AL was significant (P = 0.01).Conclusion:The effects of cyclopentolate and tropicamide drops on anterior segment parameters were similar; they did not make significant changes in K1, K2, AL, WTW, and third-generation IOL power calculation. However, ACD values significantly changed after these drops; thus, measuring anterior segment parameters before mydriatic agents should be taken into account particularly for fourth-generation IOL formulas and phakic IOL implantation. The change in pupil offset, which can be important in excimer laser and multifocal IOL applications, was not clinically significant.